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CASE STUDY
Pronounced reversible hyperammonemic 
encephalopathy associated with combined 
valproate–topiramate therapy in a 7-year-old 
girl
Sebastian Weise1, Steffen Syrbe1, Matthias Preuss1,2, Astrid Bertsche1, Andreas Merkenschlager1  
and Matthias K Bernhard1*
Abstract 
Valproate is one of the most frequently used anticonvulsive drugs in children and adults. Valproate is a generally well 
tolerated medication. However, encephalopathy with or without hyperammonemia is one of its rare adverse events. 
We present a 7-year-old girl who suffered from epilepsy with generalized tonic–clonic seizures and absence epilepsy. 
She was initially treated with topiramate. Methylprednisolone pulse therapy and long-term therapy with valproate 
were initiated due to an increase of seizure frequency. At day 5 of therapy, a further increase of seizure frequency was 
observed followed by lethargy and somnolence. Liver enzymes remained within normal range, but ammonia serum 
levels increased to a maximum of 544 mmol/l. Discontinuing valproate and starting potassium-benzoate and sodium-
phenylbutyrate improved the clinical condition and ammonia serum levels. Haemodialysis was not required. Cranial 
magnetic resonance imaging ruled out brain edema. The patient was further on successfully treated with a combina-
tion of both, topiramate and levetiracetam. Seizures did not recur and development was normal until now (3 years 
later). To the best of our knowledge, we observed the highest ammonia serum levels ever reported in valproate-
induced hyperammonemia with a complete remission of the subsequent encephalopathy. Topiramate might increase 
the risk of valproate-induced encephalopathy by carbonic anhydrase inhibition.
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Background
Valproate is one of the most frequently used anticon-
vulsive drugs in pediatric patients. It is mainly used for 
epilepsy with generalized seizures and absence epilepsy. 
Usually, valproate is well tolerated. Several adverse events 
have been associated with to VPA treatment, including 
sleepiness and weight gain and less frequently thrombo-
cytopenia, hepatopathy or encephalopathy. Hyperam-
monemia with or without evidence of hepatic toxicity is 
an important but very rare idiosyncratic adverse event 
of valproate. Valproate-induced hyperammonemic 
encephalopathy that is a potentially acute life-threatening 
condition if it is not treated appropriately.
We report a 7-year-old girl who suffered from a reversi-
ble valproate-induced hyperammonemic encephalopathy 
during combination therapy of VPA with topiramate. The 
consent to publish this case report was obtained by the 
mother of the child.
Case report
A healthy and normally developed 7-year-old girl expe-
rienced a first generalized tonic–clonic seizure, lasting 
2  min. Additionally absence seizures were recorded and 
EEG displayed typical 3  Hz spike-wave complexes. Cra-
nial magnetic resonance imaging (MRI) displayed no 
pathological findings. Topiramate was titrated slowly over 
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8 days up to 100 mg (2 × 50 mg) per day (4.4 mg/kg body 
weight/day) resulting in cessation of absence seizures.
On day 11 of treatment she experienced 20  min last-
ing generalized seizure relapse that was only termi-
nated by intravenous application of diazepam and 
midazolam. EEG recording at this time was consistent 
with absence status epilepticus. Add-on therapy with 
valproate 900  mg (2  ×  450) per day (39  mg/kg body 
weight/day) was started. An additional intravenous 
methylprednisolone pulse therapy was given for 3  days 
because of recurring generalized tonic–clonic seizures 
and absences. At the end of methylprednisolone treat-
ment (day 21) blood count, ALT (alanine transaminase), 
AST (aspartate transaminase), GGT (gamma-glutamyl 
transferase) showed normal values, ammonia 41 mmol/l 
(reference 15–55  mmol/l), valproate 96  mg/l (reference 
50–100 mmol/l).
One day after cessation of methylprednisolone pulse 
therapy (day 22) seizure frequency increased again. The 
patient appeared progressively apathetic, somnolent and 
finally comatose. Breathing was not impaired. Labora-
tory findings displayed the following: ALT 0.13  µkat/l, 
AST 0.26 µkat/l, ChE (cholinesterase) 121 µkat/l, GLDH 
(glutamate dehydrogenase) <0.02  µkat/l, NSE (neuron-
specific enolase) 12.6 µg/l, valproate 104 mg/l, ammonia 
544 mmol/l. Valproate was immediately terminated. The 
seizures were halted by infusion of midazolam and intra-
venous levetiracetam (40  mg/kg body weight/day), as 
well as intravenous sodium benzoate, sodium phenylbu-
tyrate and high-dose glucose.
For haemodialysis the patient would have been trans-
ferred to a nearby dialysis center. The medical team 
decided against the transfer because of the critical condi-
tion of the girl on day 22. On day 23 the ammonia serum 
level was decreased to 245 mmol/l. A haemodialysis was 
not seen to be justified anymore on this therapeutical 
progress.
On day 23 (the patient was comatose) EEG revealed 
generalized delta slowing and single generalized epileptic 
discharges being consisted with metabolic encephalopa-
thy. Seizures ceased quickly and the patient had a normal 
level of consciousness again (day 25).
On day 30 EEG showed no epileptiform discharges 
and ammonia serum level had returned to normal range 
(53  mmol/l). Subsequent ammonia serum levels were 
measured between 20 and 30  mmol/l. ALT, AST and 
GGT stayed within normal ranges, as well as amino acid 
levels in plasma, acylcarnitines in serum and organic 
acids in urine. The patient continued therapy with topira-
mate (100 mg per day) and levetiracetam (1,000 mg per 
day). EEG as well as cranial MRI remained normal. Sei-
zures did not recur and development was normal until 
now (3 years later).
Discussion
We present the case of a 7-year-old girl who displayed 
a distinct hyperammonemic encephalopathy. Liver 
enzymes were not elevated. Likely cause of the hyperam-
monemia was the therapy consisting of both, topiramate 
and valproate. Ammonia levels reached from normal 
serum levels within a day a maximum 544 mol/l.
Apart from pancreatitis, coagulopathy and bone mar-
row suppression, hepatic toxicity and encephalopathy 
are rare but long known adverse events of valproate ther-
apy independent of patient’s age (Gerstner et  al. 2008). 
Symptoms of valproate-induced hyperammonemic 
encephalopathy are impaired level of consciousness, focal 
neurological symptoms and increased seizure frequency 
(Eubanks et  al. 2008; Hamer et  al. 2000; McCall and 
Bourgeois 2004; Verrotti et al. 2002). Mental retardation, 
carnitine deficiency and urea cycle defects increase its 
risk (Chopra et al. 2012). Patients develop both transami-
nase elevation and isolated hyperammonemia without 
transaminase elevation with valproate-induced encepha-
lopathy (Amanat et  al. 2013; Verrotti et  al. 2002). Until 
today, the highest ammonia value of 411 mmol/l has been 
reported in a 47-year-old man who came up with a com-
pletely reversible valproate-induced encephalopathy. In 
contrast to our report, this patient’s MRI disclosed a sig-
nificant brain edema followed by cerebral atrophy (Hant-
son et al. 2005).
The present case reports the youngest patient ever 
reported with a valproate-induced encephalopathy. 
Additionally it seems to be the highest ammonia serum 
level ever published so far without leading to persistent 
cerebral damage. Fortunately, we did not observe any 
long-term pathology in the patient’s MRI which might 
be due to immediate therapy of hyperammonemia which 
resulted in normal ammonia serum levels within 8 days. 
In contrast to other cases, a mild clinical course was 
encountered despite of extraordinary high ammonia lev-
els. It may indicate a higher tolerance of ammonia in a 
child’s brain compared to adults. Methylprednisolone 
pulse therapy is more and more considered to be an effi-
cient and mainly safe therapy in child epilepsy that is 
difficult to treat (Bast et  al. 2014). Moreover, the previ-
ous methylprednisolone therapy might have prevented 
brain edema and neurological sequelae in the presented 
patient.
Carnitine administration has been shown to decrease 
hyperammonemia and hepatic toxicity in patients 
with valproate-induced encephalopathy (Mock and 
Schwetschenau 2012). However; a correlation between 
ammonia correlations and the clinical condition has not 
been proved (Lheureux and Hantson 2009). This can be 
especially helpful in mild cases when discontinuation of 
valproate therapy is not a useful option as in psychotic 
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disorder patients (Sonik et  al. 2013). Some authors rec-
ommend prophylactic carnitine supplementation in 
patients with risk factors of carnitine deficiency such as 
intake of several antiepileptic drugs, young age, intellec-
tual disability or parental feeding (Fukada et al. 2014).
There are reports about topiramate increasing the risk 
for valproate-induced encephalopathy (Gomez-Ibanez 
et  al. 2011; Hamer et  al. 2000). The youngest patient 
reported was a 15-year-old boy carrying an inverted 
duplication of chromosome 15. He developed a hyper-
ammonemic encephalopathy 2  weeks after addition of 
topiramate to his anticonvulsive therapy with valproate. 
In this case, ammonia serum levels did only double 
(Cheung et  al. 2005). A recent study from South Korea 
analyzed 8,372 patients having been treated with val-
proate, 1,236 in combination with topiramate. 11 patients 
suffered valproate-induced encephalopathy. Seven of 
these patients had been treated with the combination of 
valproate and topiramate. The authors concluded a ten-
fold higher risk of valproate-induced encephalopathy 
under combination of valproate and topiramate than 
under valproate monotherapy (Noh et al. 2013).
Hyperammonemia is supposed to inhibit glutamate 
uptake into astrocytes. Subsequently, glutamate syn-
thesis is increased and intracellular osmolarity rises. 
Thereby, cerebral edema is promoted (Verrotti et  al. 
2002). Elevated glutamate levels in serum and cerebro-
spinal fluid observed in patients with valproate-induced 
encephalopathy; support this notion (Vossler et al. 2002). 
Additionally the astrocyte function is impaired by the 
downregulation of astrocytic glutamate receptors due 
to elevated extracellular glutamate. This in turn leads to 
decreased glutathione synthesis which causes more oxi-
dative stress for neurons and glial cells (Verrotti et  al. 
2002). Topiramate might enhance this mechanism by 
two ways. It inhibits carbonic anhydrase and thus, ele-
vates ammonia serum levels by decreasing urea synthesis 
(Dodgson et al. 2000). Additionally, topiramate interacts 
with the cerebral glutamine synthetase possibly increas-
ing an already existing hyperammonemia (Hamer et  al. 
2000).
Conclusion
In summary, in patients with increasing seizure fre-
quency and valproate therapy, physicians should be 
aware of a beginning hyperammonemic encephalopathy, 
even when the patient’s consciousness is mildly impaired 
only. In suspicious situations transaminases as well as 
ammonia levels should be determined. The present 
case confirms that assumption that topiramate is has 
the potential to increase the risk of valproate-induced 
encephalopathy.
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